Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care

BACKGROUND: COVID-19 has overwhelmed health services globally. Oral antiviral therapies are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the safety and efficacy of oral favipiravir in patients hospitalised with COVID-19. METHODS: We conducted a multicentre, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Pallav L, Orton, Christopher M, Grinsztejn, Beatriz, Donaldson, Gavin C, Crabtree Ramírez, Brenda, Tonkin, James, Santos, Breno R, Cardoso, Sandra W, Ritchie, Andrew I, Conway, Francesca, Riberio, Maria P D, Wiseman, Dexter J, Tana, Anand, Vijayakumar, Bavithra, Caneja, Cielito, Leaper, Craig, Mann, Bobby, Samson, Anda, Bhavsar, Pankaj K, Boffito, Marta, Johnson, Mark R, Pozniak, Anton, Pelly, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891737/
https://www.ncbi.nlm.nih.gov/pubmed/36528039
http://dx.doi.org/10.1016/S2213-2600(22)00412-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891737/
https://www.ncbi.nlm.nih.gov/pubmed/36528039
http://dx.doi.org/10.1016/S2213-2600(22)00412-X

Ejemplares similares